COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE).

Details

Ressource 1Download: 35644101_BIB_880DB2367FE3.pdf (623.35 [Ko])
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_880DB2367FE3
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE).
Journal
ESMO open
Author(s)
Castelo-Branco L., Tsourti Z., Gennatas S., Rogado J., Sekacheva M., Viñal D., Lee R., Croitoru A., Vitorino M., Khallaf S., Šušnjar S., Soewoto W., Cardeña A., Djerouni M., Rossi M., Alonso-Gordoa T., Ngelangel C., Whisenant J.G., Choueiri T.K., Dimopoulou G., Pradervand S., Arnold D., Harrington K., Michielin O., Dafni U., Pentheroudakis G., Peters S., Romano E.
ISSN
2059-7029 (Electronic)
ISSN-L
2059-7029
Publication state
Published
Issued date
06/2022
Peer-reviewed
Oui
Volume
7
Number
3
Pages
100499
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
ESMO COVID-19 and CAncer REgistry (ESMO-CoCARE) is an international collaborative registry-based, cohort study gathering real-world data from Europe, Asia/Oceania and Africa on the natural history, management and outcomes of patients with cancer infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
ESMO-CoCARE captures information on patients with solid/haematological malignancies, diagnosed with coronavirus disease 2019 (COVID-19). Data collected since June 2020 include demographics, comorbidities, laboratory measurements, cancer characteristics, COVID-19 clinical features, management and outcome. Parameters influencing COVID-19 severity/recovery were investigated as well as factors associated with overall survival (OS) upon SARS-CoV-2 infection.
This analysis includes 1626 patients from 20 countries (87% from 24 European, 7% from 5 North African, 6% from 8 Asian/Oceanian centres), with COVID-19 diagnosis from January 2020 to May 2021. Median age was 64 years, with 52% of female, 57% of cancer stage III/IV and 65% receiving active cancer treatment. Nearly 64% patients required hospitalization due to COVID-19 diagnosis, with 11% receiving intensive care. In multivariable analysis, male sex, older age, Eastern Cooperative Oncology Group (ECOG) performance status ≥2, body mass index (BMI) <25 kg/m <sup>2</sup> , presence of comorbidities, symptomatic disease, as well as haematological malignancies, active/progressive cancer, neutrophil-to-lymphocyte ratio (NLR) ≥6 and OnCovid Inflammatory Score ≤40 were associated with COVID-19 severity (i.e. severe/moderate disease requiring hospitalization). About 98% of patients with mild COVID-19 recovered, as opposed to 71% with severe/moderate disease. Advanced cancer stage was an additional adverse prognostic factor for recovery. At data cut-off, and with median follow-up of 3 months, the COVID-19-related death rate was 24.5% (297/1212), with 380 deaths recorded in total. Almost all factors associated with COVID-19 severity, except for BMI and NLR, were also predictive of inferior OS, along with smoking and non-Asian ethnicity.
Selected patient and cancer characteristics related to sex, ethnicity, poor fitness, comorbidities, inflammation and active malignancy predict for severe/moderate disease and adverse outcomes from COVID-19 in patients with cancer.
Keywords
COVID-19, COVID-19 Testing, Cohort Studies, Female, Hematologic Neoplasms, Humans, Male, Middle Aged, Neoplasms/epidemiology, Neoplasms/therapy, Registries, SARS-CoV-2, cancer, oncology
Pubmed
Web of science
Open Access
Yes
Create date
07/06/2022 8:08
Last modification date
25/01/2024 7:39
Usage data